Life sciences investment group and part of global investment firm Carlyle, Abingworth announced last week it had exceeded its $300 million target by $56 million.
Abingworth extends its capital base for late-stage clinical programs with pharma and biotech partners London, UK and New York, USA, October 30, 2023 - Abingworth, a leading.
Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif.,. | May 11, 2023
Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif., May